Mehmet ASIL, Murat BIYIK, Saliha UYSAL, Hüseyin ATASEVEN, Ramazan DERTLİ, Ali DEMİR, Fatma YAVUZ, Hakkı POLAT

Serum ischemic modified albumin (IMA) concentration and IMA/albumin ratio in patients with hepatitis B-related chronic liver diseases

Background/aim: Albumin is the most important protein synthesized by the liver. Posttranscriptional changes occur in the molecular structure of albumin due to various factors and isoforms arise. Ischemic modified albumin (IMA) is one such isoform. This study was conducted to evaluate serum IMA concentrations in patients with hepatitis B virus (HBV)-related chronic liver diseases. Materials and methods: This study included 74 treatment-naive chronic hepatitis B patients, 25 patients with HBV-related cirrhosis, and 49 healthy controls. Serum IMA concentration was measured spectrophotometrically using the albumin cobalt binding test. Results: The mean IMA concentrations in the chronic hepatitis B group and healthy controls were 0.33 ± 0.11 ABSU and 0.27 ± 0.70 ABSU, respectively, and the difference was statistically significant (P < 0.001). Mean IMA/albumin ratios (IMAR) in the chronic hepatitis B and control groups were 0.08 ± 0.04 and 0.06 ± 0.17, respectively, and the difference was also statistically significant (P < 0.001). Higher serum IMA concentrations and IMAR were detected in patients with advanced fibrosis. Conclusion: Serum IMA concentration and IMAR are increased in patients with HBV-related chronic liver diseases and IMA and IMAR are associated with the degree of liver fibrosis. IMA and IMAR may have potential use as noninvasive markers of fibrosis in chronic hepatitis B patients.

PDF

___

1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546-1555.
2. Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int 2016; 36: 1239- 1251.
3. Bonis PA, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med 2001; 344: 452-454.
4. Roberts S, Gordon A, McLean C, Pedersen J, Bowden S, Thomson K, Angus P. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 932-937.
5. Asil M, Dertli R. Serum soluble TWEAK levels are decreased in treatment naive noncirrhotic chronic hepatitis B patients. Medicine (Baltimore). 2016; 95: e4763.
6. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999; 45 (Suppl. 4): IV1-IV11.
7. Bernardi M, Ricci CS, Zaccherini G. Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol 2014; 4: 302-311.
8. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000; 19: 311-315.
9. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006; 92: 113-114.
10. Collinson PO, Gaze DC. Ischaemia-modified albumin: clinical utility and pitfalls in measurement. J Clin Pathol 2008; 61: 1025-1028.
11. Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia? Int J Cardiol 2006; 108: 410-411.
12. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med 2011; 49: 177-184.
13. Abboud H, Labreuche J, Meseguer E, Lavallee PC, Simon O, Olivot JM, Mazighi M, Dehoux M. Ischemia-modified albumin in acute stroke. Cerebrovasc Dis 2007; 23: 216-220.
14. Gunduz A, Turedi S, Mentese A, Karahan SC, Hos G, Tatli O, Turan I, Ucar U, Russell RM, Topbas M. Ischemia-modified albumin in the diagnosis of acute mesenteric ischemia: a preliminary study. Am J Emerg Med 2008; 26: 202-205.
15. Jalan R, Schnurr K, Mookerjee RP, Sen S, Cheshire L, Hodges S, Muravsky V, Williams R, Matthes G, Davies NA. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009; 50: 555-564.
16. Cakir M, Karahan SC, Mentese A, Sag E, Cobanoglu U, Polat TB, Erduran E. Ischemia-modified albumin levels in children with chronic liver disease. Gut Liver 2012; 6: 92-97.
17. Zuwala-Jagiello J, Warwas M, Pazgan-Simon M. Ischemiamodified albumin (IMA) is increased in patients with chronic hepatitis C infection and related to markers of oxidative stress and inflammation. Acta Biochim Pol 2012; 59: 661-667.
18. Chen CY, Tsai WL, Lin PJ, Shiesh SC. The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease. Clin Chem Lab Med 2011; 49: 1817-1821.
19. Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, Honda SA, Rios CN, Sugiyama CE, Ha CE. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003; 49: 581-585.
20. Spinella R, Sawhney R, Jalan R. Albumin in chronic liver disease: structure, functions and therapeutic implications. Hepatol Int 2016; 10: 124-132.
21. Domenicali M, Baldassarre M, Giannone FA, Naldi M, Mastroroberto M, Biselli M, Laggetta M, Patrono D, Bertucci C, Bernardi M. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology 2014; 60: 1851-1860
22. Oettl K, Stadlbauer V, Petter F, Greilberger J, Putz-Bankuti C, Hallström S, Lackner C, Stauber RE. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 2008; 1782: 469-473.